Table 1 Characteristics for each challenge dose group

N (%, total)

621 (30.2%)

812 (39.4%)

625 (30.4%)

2058 (100.0%)

-

OFC positive (%)

213 (34.3)

191 (23.5)

122 (19.5)

526 (25.6)

< 0.001

Anaphylactic reaction (%)

47 (7.6)

41 (5.0)

24 (3.8)

112 (5.4)

0.014

Age in months

[IQR]

24.0

[15.0–49.0]

30.5

[19.0–58.0]

37.0

[25.0–60.0]

31.0

[19.0–57.0]

< 0.001

History of anaphylaxis to HE (%)

128 (20.6)

158 (19.5)

67 (10.7)

353

< 0.001

History of immediate reaction to HE (%)

454 (73.1)

618 (76.1)

484 (77.4)

1556 (75.6)

0.191

Complete elimination of HE (%)

304 (49.0)

78 (9.6)

9 (1.4)

391 (19.0)

< 0.001

History of wheezing (%)

217 (35.0)

255 (31.4)

203 (32.5)

675 (32.8)

0.350

Atopic dermatitis (%)

451 (72.7)

560 (69.0)

402 (64.3)

1413 (68.7)

0.006

Total IgE (IU/mL)

[IQR]

206

[78.3–635]

242

[78.0–901]

183

[65.0–643]

217

[73.0–722]

0.034

EW-sIgE (kU/L)

[IQR]

19.6

[7.1–48.6]

11.7

[4.1–29.4}

5.5

[1.9–16.7]

11.0

[3.56–30.1]

< 0.001

OVM-sIgE (kU/L)

[IQR]

9.9

[2.5–29.5]

4.8

[1.0–14.3]

2.2

[0.4–6.7]

4.53

[0.88–15.3]

< 0.001